PPCO: Penwest Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PPCO: Penwest Pharmaceuticals

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

From: keokalani'nui	11/22/2004 1:10:44 PM
	of 5

Under the terms of the SPA, Endo will conduct a 12-week, multicenter, double-blinded, placebo-controlled Phase III trial of oxymorphone ER in patients with chronic low back pain who have had no prior or recent treatment with opioid analgesics. So long as they've got enough patients, how could this go wrong?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext